RxDoctor Payments Data

Thomas Bateman, MD

Family Medicine · Mobile, ALNPI 1649806613

Payments from drug & device makers

$2,843in general payments, 2019–2025

Across 142 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$616
  • Novo Nordisk$517
  • Lilly USA, LLC$469
  • AbbVie$357
  • Bayer$136
  • Amgen$130
  • plus $618 from 15 others

What the payments were for

  • Food & beverage$2,843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,843 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$49,937
Medicare patients
221
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$17,151
MounjaroTirzepatide11$13,146
OzempicSemaglutide13$11,793
JanuviaSitagliptin Phosphate12$10,564
Atorvastatin Calcium102$1,316
Rosuvastatin Calcium70$1,271
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide23$990
Amlodipine Besylate126$617
Pantoprazole Sodium44$558
Losartan Potassium44$535
Ezetimibe15$489
Omeprazole33$366
Olmesartan Medoxomil16$317
Albuterol Sulfate HfaAlbuterol Sulfate13$285
Potassium Chloride23$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$122$17,15115 claims
Lilly USA, LLCMounjaro$469$13,14611 claims
Novo NordiskOzempic$517$11,79313 claims
MerckJanuvia$42$10,56412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →